Drawing researchers from the UK, continental Europe, and the US, last week s IBC conference Proteomics and the Proteome in Geneva, Switzerland, painted a picture of proteomics in its most cosmopolitan of guises. Subscribers: click headline for more.
Just over two years after GeneProt s founders met in the business travelers lounge of Boston s Logan Airport to start one of the first large-scale proteomics companies, GeneProt s flagship facility in Geneva is evidence that they have made great strides towards maturity Subscribers: click headline for more.
In a talk that illustrated the plethora of proteomics technologies available for researchers with ample resources, Roche s proteomics director Hanno Langen shared new developments in his approach to separating and analyzing proteins last week at the IBC Proteomics and the Proteome conference in Geneva, Switzerland. Subscribers: click headline for more.
Bowing to pressure from its UK-based rival, GeneProt has agreed to pay $1 million in cash and equity to Oxford GlycoSciences for the right to license two patents covering a procedure for separating and analyzing proteins using an automated 2D gel electrophoresis platform, the companies said last week. Subscribers: click headline for more.
Last July, the National Institutes of Health and the Food and Drug Administration announced that they would begin tripling the amount of annual funding for a new clinical proteomics program. Subscribers: click headline for more.
Analyzing proteins for posttranslational modifications using mass spectrometry is a tricky business, usually requiring many rounds of analysis of peptide fragments. Wouldn t it be nice to be able to stick an entire protein into the mass spec and get out all of the modifications? Subscribers: click headline for more.
Despite cash-flow problems and the termination of its research partnership with antibody-manufacturer Biosite, Large Scale Biology still has plans to release antibody chips for use in commercial research by early 2003, LSBC CEO Bob Erwin told ProteoMonitor last week. Subscribers: click headline for more.
Hybrigenics has signed a research agreement with Mindsense Biosystems, marking the first partnership under which the Paris-based company will own rights to develop therapeutics from the resulting data, Hybrigenics said last week. Subscribers: click headline for more.
If you thought microarrays were tiny, brace yourself for the next small thing: nanoarrays. In last week s Sciencexpress, Chad Mirkin and colleagues from Northwestern University and the University of Chicago describe their protein arrays with feature sizes of 100 to 350 nanometers, producing an array about 200,000 times more dense than the yeast proteome array most recently reported in the literature.. Subscribers: click headline for more.
Motivated by the desire to improve upon the ICAT reagent technology, Andrew Emili and his colleagues at the University of Toronto have devised a tagging technique for performing de novo peptide sequencing and quantitative protein profiling experiments that they claim is cheaper and less complicated than its more established cousin.. Subscribers: click headline for more.
While HUPO picks the brains of experts for ideas on how to coordinate large-scale partnerships between academia and industry, a consortium of nine academic groups and three biotechnology companies in Germany has picked the brain for a project that aims to develop and evaluate new proteomics technologies. . Subscribers: click headline for more.